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1. Introduction 
Inborn errors of metabolism (IEM) comprise a large group of more than 500 different rare 
genetic disorders. They arise due to mutations in genes encoding a single enzyme in metabolic 
pathways. Some of these disorders are very rare, whereas certain other disorders are more 
common. There are considerable racial and ethnic differences in the incidence pattern of these 
disorders. Aminoacidurias like phenylketonuria are common in the Western population; in 
Asian countries including India, organic acidurias like propionic acidurias, methyl malonic 
acidurias and maple syrup urine disease are more common. Clinical presentation of IEM is 
varied and it affects multiple organ systems, including CNS. Indeed CNS involvement is one 
of the most common presenting symptoms. The diseases can appear immediately after birth; 
or sometimes it may be delayed, even appearing in adult life.  
In this chapter we shall describe our experience with metabolic screening in the last 5 years. 
This is followed by a presentation of some important case histories along with their 
laboratory work-up. We then go on to discuss the current global status in diagnosis and 
management of these diseases. It should be emphasized at the beginning itself that our 
laboratory (Metabolic Disorders Laboratory, Amrita Institute of Medical Science, Kochi, 
Kerala, S. India) is a referral center for the state of Kerala as well as the neighboring states in 
South India. Hence the studied population represents children who are suspected to have 
IEM or are high-risk individuals, or who have been referred from other hospitals in this part 
of India. Hence the results described do not reflect the population incidence.  
If these patients are not diagnosed and treated early in life, they go on to have irreversible 
damage. Many body systems are affected, and the predominant damage will be to the 
central nervous system. The babies may develop permanent mental retardation, growth 
retardation, intractable seizures, cerebral palsy etc.  
2. Objectives 
8361 patients were screened for different metabolic disorders during the time period from 
September 2006 to August 2011. The screening panel included tests for aminoacidurias, 
organic acidurias, disorders of carbohydrate metabolism (including galactosemia, 
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glycosuria, fructosuria, pentosuria, mucopolysaccharidoses etc), congenital adrenal 
hyperplasia, pheochromocytoma, hyperhomocysteinemia, porphyrias etc.  
3. Methods  
Patients admitted to Amrita Institute of Medical Sciences, Kochi and other hospitals in Kerala 
State, South India with signs and symptoms suggestive of metabolic disorder were tested. 
Neurological symptoms of the patients included psychomotor delay, mental retardation, 
seizures, dystonia, ataxia, lethargy, coma, encephalitis, speech delay, hyperactivity etc. Non-
neurological symptoms were failure to thrive, organomegaly, vomiting, skin rashes, metabolic 
acidosis, hyperammonemia, hypoglycemia, lactic acidosis and ketonuria. 
The breakup of different tests are as follows – (1) Total number of tests – 8361 (2) Urine 
screened for metabolic disorders (panel including amino acids, organic acids, carbohydrates, 
ketone bodies etc) – 1940 (3) Amino acid screening by HPLC – 519; Organic acid screening 
by HPLC - 420 (4) Homocysteine estimation – 953 (5) VMA estimation – 582 (6) Porphyrias – 
266 (7) 17  hydroxy progesterone estimation (for congenital adrenal hyperplasia) – 1155 (8) 
Adenosine deaminase estimation – 2406 and (9) Other tests – 540 (Myoglobin, 5 HIAA, 
lipoprotein electrophoresis, glucose 6 phosphate dehydrogenase, homocystinuria etc). 
Methodologies are given under each concerned section. 
4. Results 
The breakup of positive cases is as follows – Aminoacidurias – 32, organic acidurias – 51 
(confirmed cases), hyperhomocysteinemia – 285, pheochromocytomas and neuroblastomas 
– 44, elevated adenosine deaminase levels – 358 and congenital adrenal hyperplasia – 309. 
Further discussion is limited to aminoacidurias, organic acidurias, hyperhomocysteinemia, 
pheochromocytomas and neuroblastomas, since other disorders will not affect the brain. 
We have divided this chapter into 3 major sections: Each of these sections will discuss the 
results and recent review of literature. Some rare and interesting cases are also discussed 
under the concerned sections. Section 1 – Aminoacidurias and organic acidurias; Section 2 – 
Homocysteine, Section 3 – Pheochromocytoma and neuroblastoma. Section 1 on 
aminoacidurias and organic acidurias is divided into 4 sub-sections: 1.1 – Maple syrup urine 
disease, 1.2 – Methyl malonic acidurias and propionic acidurias, 1.3 – Phenylketonuria and 
1.4 – Nonketotic hyperglycinemia.  
5. Section 1: Amino acidurias and organic acidurias 
5.1 Materials and methods 
1940 urine samples were initially screened for different aminoacidurias and organic 
acidurias. Simple screening tests and thin layer chromatography were used for screening. 
519 samples were analyzed further for aminoacidurias and 420 samples were analyzed for 
organic acidurias by HPLC. 20 ml fresh urine samples and 3 mL EDTA blood samples were 
collected under aseptic precautions for the analysis. 
5.1.1 HPLC method of amino acid analysis 
Analytical Conditions were as follows - Column- LUNA C-18, Mobile phase A: 5 mM 
sodium phosphate buffer with pH 7.0, Mobile Phase B: 100% Acetonitrile. Gradient Elution, 
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Flow Rate- 1.0 ml/ min, Temperature- 40 C, Detection- Absorption (254 nm). Samples were 
deproteinized and treated with phenyl isothiocyanate (PITC) and triethylamine (TEA) prior 
to injection (pre column derivatization). 
5.1.2 HPLC method of organic acid analysis 
Analytical Conditions were as follows - Column: 4.6 mm * 250 cm, Lichrocart 250-4 
Lichrosorb RP –18 (Phenomenex), Mobile phase: 0.01M KH2PO4/H3PO4 (pH 3.5), Flow rate: 
1 ml/min, Detection: U V 206 nm, PDA detector, Column Oven Temperature: 25 C. Urine 
samples were also deproteinized prior to injection.  
5.1.3 Results 
We detected a high incidence of aminoacidurias and organic acidurias in this population. 
Among organic acidurias, higher prevalence of propionic aciduria (PAA), 16 cases, and 
methylmalonic aciduria (MMA), 15 cases, were seen. 13 cases of maple syrup urine disease 
(MSUD), 1 case of isovaleric aciduria and 6 cases of alkaptonuria were detected. 5 cases of 
tyrosinemia, 4 cases of nonketotic hyperglycinemia (NKH) and 3 cases of phenyl ketonuria 
(PKU) were also confirmed. There was one case of non- PKU hyperphenylalaninemia. One 
patient was detected to have hypermethioninemia (484 mol/L). Mild elevation of 
individual amino acids was seen in a number of cases and was not considered to be 
characteristic of any individual aminoaciduria. This included glycine (59 cases), alanine (44 
cases), proline (17 cases), histidine (8 cases) and lysine (2 cases). This probably is a 
representation of increased catabolic state in these patients. 
5.1.4 Review of literature 
Lou et al (2011) studied 552 children at high risk by MS/MS in China and report 64 children 
with IEM including predominantly organic acidurias and some aminoacidurias. Niu et al 
(2010) did population screening on about 1.5 million Taiwanese neonates by MS/MS and 
found that PKU, MSUD, GA-1 and MMA were the commonest disorders. Cakmakci et al 
(2010) reports the use of proton MR spectroscopy and diffusion weighted MR imaging in the 
diagnosis of children with neurometabolic brain disorders including MSUD, Canavan 
disease and galactosemia. Walter et al (2009) studied cord blood in a large cohort of 24, 983 
births for various IEM. Cord blood screening did not detect PKU, MSUD, argininosuccinic 
acidurias, MMA, glutaric aciduria type 2, MCAD deficiency etc which was diagnosed later. 
They conclude that cord blood screening is not recommended for IEM. 
Wasant et al (2008) identified 12 cases of organic acidurias in 365 patients over 3 years from 
Thailand. The cases include alkaptonuria, IVA, PA, MMA, GA-I, GA-II and MCD. 
Shigematsu et al (2010) identified 1065 cases of IVA from 146, 000 neonates screened over 
three years in a Japanese population. 
5.2 Section 1.1: Maple syrup urine disease  
5.2.1 Case report 
We report here two cases of maple syrup urine disease (MSUD). Patient 1 presented at 3 
months of age with excessive irritability, abnormal posturing since birth and delayed 
developmental milestones. History of sibling death at Day 15 of life. The clinician reported 
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abnormal urine odor and clinical suspicion was MSUD, isovaleric aciduria or PKU. 
Laboratory analysis revealed ketonuria and metabolic acidosis. HPLC analysis of amino 
acid confirmed MSUD (Figure 1). Child died immediately afterwards. 
Patient 2 presented at Day 12 with metabolic acidosis, abnormal urine odor, ketonuria and 
hepatosplenomegaly. Blood and urine studies revealed the diagnosis of MSUD. Aggressive 
treatment was started including branched chain amino acid restricted diet and 
supplementation. Patient has survived until 3 years of age, without any episode of 
exacerbation afterwards. Patient is on follow up. Levels of leucine, isoleucine and valine 
came down to normal level (Table 1). 
In the case of the first patient (Patient 1), diagnosis was delayed and hence treatment could 
not be instituted and the baby died. But in the second case (Patient 2) diagnosis and 
treatment was started early in life and outcome was better. These two case studies indicate 
the importance of early diagnosis and treatment in MSUD. 
5.2.2 Biochemical abnormalities 
The name originates from the characteristic smell of urine (similar to burnt sugar or maple 
sugar) due to excretion of branched chain keto acids. Maple syrup urine disease (MSUD) or 
branched chain ketoaciduria is caused by deficiency of branched chain keto acid 
dehydrogenase complex (BCKAD). The basic biochemical defect is deficient decarboxylation 
of branched chain keto acids (BCKA). It leads to accumulation of branched chain amino 
acids (BCAA) Leucine, Isoleucine and Valine and corresponding branched chain  keto 
acids (BCKA). Five distinct phenotypes are present: Classic, Intermediate, Intermittent, 
Thiamine-responsive and Dihydrolipoyl dehydrogenase (E3) deficient. 
 
Fig. 1. Chromatogram of patient 1 (Leucine 2240 mol/L, Valine 411 mol/L, Isoleucine  
180 mol/L; Normal Leu <150, Val <255 and Ile <80mol/L) 
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11.04.2009 518 3020 437 
25.07.2009 194 1708 350 
15.03.2010 98 424 166 
06.08.2010 135 479 69 
Table 1. Serial levels of Branched chain amino acids in patient 2 diagnosed with MSUD – 
Classic MSUD is the most common and is the most severe type. It has a neonatal-onset type 
of encephalopathy. Other types generally have onset by 2 years. BCAA, generally Leucine, is 
elevated in blood and urine. Presence of alloisoleucine is diagnostic. It has autosomal 
recessive inheritance. Worldwide frequency is 1 in 1,85,000.  
BCAA comprise 35% of indispensable amino acids in muscles. Majority of untreated classic 
patients die within the early months of life from recurrent metabolic crises and neurologic 
deterioration. Treatment involves long-term dietary management and aggressive 
intervention during acute metabolic decompensation. Age at diagnosis and subsequent 
metabolic control are the most important determinants of long-term control. Patients in 
whom treatment is initiated after 10 days of age rarely achieve normal intellect.   
Disease starts in the first week of life. It is characterized by convulsions, severe mental 
retardation, vomiting, acidosis, coma and death within the first year of life. Urine contains 
branched chain keto acids, valine, leucine and isoleucine. Rothera's test is positive, but 
unlike in cases of ketoacidosis, even boiled and cooled urine will give the test. Diagnosis 
depends on enzyme analysis in cells. Diagnosis should be done prior to 1 week after birth. 
Giving a diet low in branched chain amino acids. Mild variant is called intermittent 
branched chain ketonuria. This will respond to high doses of thiamine. This is because the 
decarboxylation of the BCKA requires thiamine. Liver transplantation has been successfully 
tried in some cases of MSUD. 
5.2.3 Review of literature 
Chen et al (2010) has reviewed 15 cases of MSUD from China and they suggest that early 
diagnosis and treatment can help prevent neurologic signs. Pangkanon et al (2008) report 13 
cases of MSUD in Thai infants. All patients had neurological manifestations and psychomotor 
retardation. Lee et al (2008) report 47 Filipino patients with MSUD which is the commonest 
IEM in Philippines. They report that clinical outcome is poor in their series of patients.  
Barschak et al (2009) report MSUD is associated with lipid peroxidation. They also report 
reduced amino acids methionine and tryptophan, which are amino acids with antioxidant 
activity. Mescka et al (2011) report protective effect of carnitine against oxidative stress 
induced by MSUD. 
Ribeiro et al (2008) report that the major metabolites accumulating in MSUD disturb brain 
aerobic metabolism by compromising the citric acid cycle and the electron flow through the 
respiratory chain. They hypothesize that this might explain the neurological features in MSUD.  
Brunetti-Pierri et al (2011) report successful use of phenylbutyrate in bringing down branched 
chain amino acid levels in MSUD. Shellmer et al (2011) studied 14 patients who received liver 
transplantation for MSUD and found that liver transplantation reduced further CNS damage 
in these patients. Strauss et al ((2010) has suggested novel therapeutic modalities in the 
management of MSUD based on their experience in treating 79 patients over 20 years. 
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Zinnanti et al (2009) report that rapid brain leucine accumulation displaces other essential 
amino acids resulting in neurotransmitter depletion and disruption of normal brain growth 
and development in mouse model. They also report that administration of norleucine 
reduces branched chain amino acid accumulation in brain, blood and milk. Norleucine also 
substantially delayed encephalopathy in intermediate type MSUD. They conclude that brain 
damage in MSUD might be due to two factors – (1) Neurotransmitter deficiencies and 
growth restriction associated with BCAA accumulation, and (2) Energy deprivation through 
Krebs’ cycle disruption associated with BCAA accumulation.  
Ibarra-Gonzalez et al (2007) report increased mortality and disabilities, especially neurological, 
in a cohort of 36 patients with MSUD from Mexico. Kowalik et al (2007) report deficiency of 
iron, zinc, copper, Vitamin B1, B2, niacin and Vitamin C in treated MSUD patients. Wajner et 
al (2007) report that BCAA inhibited Na-K ATPase pump in the brain and alanine prevented 
this inhibition. They conclude that this mechanism might contribute to neurological damage in 
MSUD, as Na-K ATPase pump is a critical enzyme for normal brain development and 
functioning. Bridi et al (2005) also report that alpha keto acids accumulating in MSUD 
stimulate lipid peroxidation and reduce antioxidant defense in cerebral cortex.  
There are a large number of studies which report on CT and MR scans of the brain in MSUD 
[Cakmakci et al (2010), Tu et al (2005), Sener (2004), Schonberger et al (2004) and others]. 
Bindu et al (2007) have described neuroradiological findings in 3 patients with intermediate 
MSUD from South India. 
5.3 Section 1.2: Methylmalonic aciduria and propionic aciduria  
5.3.1 Results 
We have detected 16 cases of propionic acidurias and 15 cases of methyl malonic acidurias in 
our study. Most of these patients had neurological manifestations and presented with 
metabolic acidosis and/or hyperammonemia. 60% of patients had neurological abnormalities 
including psychomotor delay, mental retardation, seizures, dystonia, ataxia, lethargy, 
extrapyramidal symptoms, encephalopathy, coma, visual deficiency, speech delay etc.  
 
Fig. 2. Screening test for methyl malonic aciduria (Emerald green is positive test; other test 
tube is control urine sample) 
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Abnormal MRI findings were found in 11 patients including macrocephaly, cerebral atrophy 
and cerebral edema. Further details of this work can be seen in our paper (Narayanan et al, 
2011; Vaidyanathan et al, 2011). Figure 2 gives a screening test for methyl malonic acid. 
5.3.2 Biochemical abnormalities 
Propionyl CoA is primarily converted to methyl malonyl CoA, which is subsequently 
converted to Succinyl CoA. Enzymes involved are propionyl CoA carboxylase, methyl 
malonyl CoA racemase and methyl malonyl CoA mutase. Biotin is needed for first and 
cobalamin for the third enzyme. Propionyl CoA carboxylase has two non-identical sub-units 
 and  biotin binds to  sub-units, located on chromosomes 13 and 3 respectively. Methyl 
malonyl CoA mutase has 2 identical  sub-units, located on chromosome 6. 
Holocarboxylase deficiency and biotinidase deficiency are known. Other known disorder is 
multiple carboxylase deficiency. PCC deficiency leads to propionic acidemia, and elevated 3 
hydroxy propionate, methyl citrate, tiglyl Glycine, and unusual ketone bodies in urine. 
Severe metabolic ketoacidosis in neonatal period is seen. Alkali therapy and protein 
restriction are needed. 
Inherited deficiency of the mutase enzyme or abnormalities in cobalamin can result in 
methyl malonic aciduria. Neonatal or infantile metabolic ketoacidosis are the hallmarks. 
Patients with abnormal binding ability of enzyme to cobalamin, cannot be treated by 
cobalamin therapy. These cases may be treated with dietary protein restriction and 
antibiotic therapy. Other patients respond to cobalamin or hydroxycobalamin therapy. This 
can be used in combination with dietary protein restriction. Therapy has been found to 
reduce methyl malonate levels. Mutations leading to impaired adenosyl cobalamin and 
methyl cobalamin and deficient activity of methyl malonyl CoA mutase and N5 methyl 
tetrahydro folate reductase. Homocysteine methyl transferase have methyl malonic aciduria 
combined with homocystinuria. Features include failure to thrive, developmental 
retardation, megaloblastic anemia and macrocytosis. Therapy includes protein restriction, 
pharmacological doses of hydroxocobalamin and betaine supplementation.  
Both disorders are inherited as autosomal recessive disorders. Prenatal diagnosis is possible 
by enzyme assays on chorionic villus biopsy or cultured amniotic cells and chemical 
determinations on amniotic fluid or maternal urine. 
5.3.3 Review of literature 
Liu et al (2010) reports 24 mutations in the MMACHC gene to be responsible for cblC type 
of combined methyl malonic aciduria and homocystinuria in 79 unrelated Chinese patients. 
5 mutations are responsible for 80% of cases and suggest a role for mutation detection in 
early diagnosis. Cosson et al (2009) reports on long term outcome of 30 French patients with 
methyl malonic acidurias. 15 patients had neonatal onset, 13 had severe neurological 
involvement, 14 had chronic renal failure and 5 died during a metabolic crisis. Patients with 
a mut(0) phenotype had a severe phenotype and early and more severe CRF than patients 
with mut-/cblA phenotype.  
Chandler et al (2007) reports successful use of adenoviral mediated gene therapy for 
methylmalonic aciduria in murine models and human patients with MUT gene mutation. 
Yang et al (2006) and other authors report that in China methylmalonic acidurias is more 
commonly associated with homocysteinemia. Filippi et al (2010) describes the use of N – 
www.intechopen.com
 
Brain Damage – Bridging Between Basic Research and Clinics 
 
64
carbamyl glutamate in the emergency management of hyperammonemia in neonatal acute 
onset propionic aciduria and methylmalonic aciduria. Perez et al (2009) describes 
pseudoexon exclusion by antisense therapy in MMA. Haas et al (2009) report that 
Coenzyme Q (10) is significantly decreased in MMA patients.  
Wajner et al (2009) identified 34 patients with MMA and 18 patients with PA from Brazil in 
15 years. Zwickler et al (2008) reviews MMA patients in 14 centers in Germany and outlines 
the management principles. Most centers used hydroxocobalamin or cyanocobalamin for 
cobalamin-responsive patients while cobalamin – nonresponsive patients are supplemented 
with carnitine. Intestinal decontamination by antibiotic therapy, D-A-CH or Dewey 
recommendations for protein therapy and precursor-free amino acid supplements were 
used by most centers. Zhang et al (2007) studied the clinical picture of 96 patients with 
MMA over a 10 year period. Most of the patients had neurological abnormalities including 
developmental delay, seizures, psychomotor degeneration and motor disorders. A 
significant proportion of patients had MMA along with homocysteinemia.  
Longo et al (2005) describes neurological abnormalities in MMA patients detected by MRI 
and 1H-MRS. Burlina et al (2003) and Rossi et al (2001) also describe neurological damage in 
MMA. Bodamer et al (2005) studied creatine metabolism in MMA patients and found that 
guanidinoacetate is elevated. They suggest that guanidinoacetate may be responsible for 
neurotoxicity in MMA. Vara et al (2011) discusses the importance of liver transplantation in 
propionic aciduria (PA) patients. Liver transplantation reduces the risk of metabolic 
decompensation and improves the quality of life. Romano et al (2010) report that 
cardiomyopathy in PA is reversible with liver transplantation. 
Ah Mew et al (2010) also reports that NCG reduces ammonia and glutamine and induces 
ureagenesis in PA. Schwahn et al (2010) also reports of NCG in PA. Chandler et al (2011) 
describes the use of gene therapy using adeno associated virus (AAV8) for the treatment of 
PA. Ribas et al (2010) report that PA and MMA induce DNA damage and L – carnitine 
prevents this damage. Haberlandt et al (2009) report seizures in 9 patients with PA and 
hypothesize that some intermediates might be involved in the pathogenesis of epilepsy. 
Rigo et al (2006) suggests the involvement of NMDA receptors in the pathogenesis of 
neurological manifestations. 
de Keyzer et al (2009) report multiple OXPHOS deficiency in liver, kidney, heart and 
skeletal muscle in patients with MMA and PA. Desviat et al (2009) report high frequency of 
large gene deletions in PA patients. This finding underscores the need for gene dosage 
analysis in additional to mutation testing in PA patients. Perez Cerda et al (2004) report the 
utility of prenatal diagnosis by molecular methods in 19 unrelated families with PA. 
5.4 Section 1.3: Phenylketonuria (PKU)  
5.4.1 Case report 
We hereby report two patients with PKU. Patient 3 is a 21 year old woman with sub-normal 
intelligence and suspected to have phenylketonuria, though not confirmed previously 
(Phenylalanine level – 1427 mol/L, Normal <65 mol/L). Patient 4 is 19 years old and is 
the sibling of Patient 2 (Phenylalanine level 1177 mol/L). She also had sub-normal 
intelligence. Both patients had pleasant social manners. At the time of presentation, Patient 3 
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was pregnant and had hence sought advice. Three months after presentation, Patient 4 also 
became pregnant. Both patients were confirmed to have phenylketonuria by urine and 
blood tests for phenylalanine. Phenylalanine restricted diet was advised, but compliance 
was not satisfactory and phenylalanine levels remained above 1000 mol/L. Patient 3 
delivered and child suffered from clinical and laboratory signs of maternal 
hyperphenylalaninemia. Child died in the immediate post natal period. The child of the 
other patient died in utero.  
5.4.2 Biochemical abnormalities 
Hyperphenylalaninemias are due to disorders of phenylalanine hydroxylation reaction. The 
minimum requirements for phenylalanine metabolism to occur are the enzyme phenyl 
alanine hydroxylase (PAH), molecular oxygen (O2), L-Phenyl Alanine and 
tetrahydrobiopterin (BH4). Other components include dihydrobiopterin (DHPR), reduced 
pyridine nucleotide, 4carbinolamine dehydratase (for BH4 recycling), GTP cyclohydrolase 
(GTP – CH) and 6 pyruvoyl tetrahydropterin synthase (6 PTS). Hyperphenylalaninemia is 
defined as Phenylalanine levels above 120 µM (2 mg/dl). Normal plasma level of phenyl 
alanine is 58±15 µM. 
Phenylalanine cannot be converted to tyrosine. So phenylalanine accumulates. Phenylalanine 
level in blood is elevated. So alternate minor pathways are opened. Phenyl ketone (phenyl 
pyruvate), phenyl lactate and phenyl acetate are excreted in urine. Phenyl pyruvate inhibits 
pyruvate decarboxylase enzyme in brain, but not in liver. Hence myelin formation defects 
and mental retardation are seen. Brain effects are due to phenylalanine and its metabolites 
(phenyl ketones, namely Pyruvate, lactate, acetate, acetyl glutamine and ethyl amine) that 
accumulate via alternate pathway. Myelination and protein synthesis are affected and there is 
deficient neurotransmitter supply. Peculiarities of gait, stance and sitting posture are 
additional features. Brain calcification may be seen in DHPR deficient type.  
Phenylketonuria is well known for the neurological manifestations. The classical PKU child 
is mentally retarded with an IQ of 50. About 20% inmates of psychiatric hospitals may have 
PKU. Agitation, hyperactivity, tremors and convulsions are often manifested. This may be 
because phenylalanine interferes with neurotransmitter synthesis. The child often has 
hypopigmentation, explained by the decreased level of tyrosine. Phenyl lactic acid in sweat 
may lead to mousy body odor. 
5.4.3 Maternal hyperphenylalaninemia  
Female child, on growing to adulthood may become pregnant (maternal hyper 
phenylalaninemia). Then again special diet is to be given, because the increased 
phenylalanine level will affect the brain development of the fetus. Maternal 
hyperphenylalaninemia (PKU embryo-fetopathy) cause embryopathy/ fetopathy 
comprising impaired growth, congenital cardiac malformations, microcephaly and mental 
retardation in the embryo/fetus. Fetal phenylalanine level is 1.5 – 2 fold higher than 
maternal blood level. Further fetal blood brain barrier concentrates phenylalanine to another 
2-4 fold. Intraneuronal phenylalanine level of 600mol interferes with brain development. 
Phenylalanine restricted diet should be started at least 3 months prior to planned 
pregnancy. Phe level in mother to be maintained at 60-180mol/L. Linoleic and linolenic 
acid supplements should be maintained at high level. 
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5.4.4 Review of literature 
Oddason et al (2011) report 27 patients diagnosed with PKU in Iceland since 1947. Classical 
PKU is the commonest type. Macdonald et al (2011) in a study from UK report that PKU 
patients, especially older, are not fully compliant with treatment and hence have higher than 
acceptable phenylalanine levels. At the same time, van Rijn et al (2011) report that well-
controlled adult PKU patients can tolerate larger dietary variations in phenylalanine levels. ten 
Hoedt et al (2011) report that high phenylalanine levels can directly affect mood and sustained 
attention in adult PKU patients (Randomized, double-blind, placebo-controlled, crossover trial). 
Ribas et al (2011) suggest that oxidative stress may play a role in pathogenesis of PKU. 
Sanayama et al (2011) provide experimental evidence for the same and report that oxidative 
stress status is closely linked with phenylalanine levels. Sitta et al (2011) report that 
administration of L-carnitine and selenium can reduce oxidative stress in PKU patients.  
Hanley (2011) in a review states that “non-PKU mild hyperphenylalaninemia” (MHP) also 
might have neuropsychological function deficits and therefore may need treatment with 
tetrahydrobiopterin and/or phenyl alanine restricted diet. Campistol et al (2011) discusses 
on the extent of neuro-congitive dysfunction in mild PKU (mPKU) and conclude that further 
studies are needed on mPKU to clearly answer this question. van Spronsen (2011) addresses 
the question on treatment of mPKU and reaches similar conclusion. 
Vernon et al (2010), Trefz et al (2010), Harding (2010), Burton et al (2010), Somaraju & 
Merrin (2010) and others report that saptopterin hydrochloride, a synthetic analog of 
tetrahydrobiopterin, is a promising new drug in the treatment of PKU. This modality of 
treatment is especially important considering the report by Enns et al (2010) who state that 
PKU treated with diet alone has sub-optimal outcome with relation to neurocognitive, 
psychological and physical parameters. Lee et al (2009) and others however, report better 
outcome with dietary treatment alone. Blau et al (2010) reports on the management practices 
in PKU in 165 PKU centers in 23 European countries. They emphasize that treatment 
recommendations vary tremendously in different countries and hence there is an urgent 
need to pool long-term data in registries to generate evidence based international 
guidelines. Ahring et al (2009) and van Spronsen (2009) give similar reports. 
Rocha and Martel (2009) report the use of large neutral amino acids in the treatment of PKU. 
The same carrier transports phenylalanine as well as large neutral amino acids into the 
brain; hence their use diminishes toxicity due to phenylalanine. Weigel et al (2008) report 
low free carnitine levels in PKU patients given low phenylalanine diet. They suggest that 
carnitine level should be monitored in PKU patients. Sitta et al (2009) reach similar 
conclusions. A study by Maillot et al (2008) reports on the importance of maintaining blood 
phenylalanine during pregnancy. They conclude that maintenance of maternal blood 
phenylalanine level within the target range predicts good offspring outcomes; and further 
suggests that variations even within that range should be avoided.  
5.5 Section 1.4: Nonketotic hyperglycinemia  
5.5.1 Case report 
We report here one male baby (Patient 5) with intractable seizures who was 7 days old. All 
antiepileptic drugs were tried without any response. The parents were complaining about 
medical negligence. HPLC analysis of amino acid revealed nonketotic hyperglycinemia 
(NKH) (Figure 3). Even though the child could not be revived; this case shows the 
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importance of workup for inborn errors of metabolism to reach a diagnosis. In this case, the 
diagnosis was important for the doctor to counsel the parents appropriately. 
5.5.2 Biochemical abnormalities 
It is due to defect in glycine cleavage system. Glycine level is increased in blood, urine and 
CSF. Severe mental retardation and seizures are seen. There is no effective management. 
Large quantities of Glycine accumulate in all body tissues including CNS. Diagnosis is 
established by CSF: plasma Glycine concentration >0.08. Patients have a neonatal phenotype 
and present in the first few days of life with lethargy, hypotonia and myoclonic jerks and 
progressing to apnea and death. Surviving infants have intractable seizures and profound 
mental retardation. Later-onset children have progressive spastic diplegia and optic 
atrophy, but mental retardation and seizures may not be seen. Transient NKH is also 
reported. It is inherited as an autosomal recessive disorder. In neonatal NKH CSF: plasma 
ratio may be 0.09-0.25 and in atypical NKH it is 0.09 – 0.10. Normal ratio is 0.012 – 0.040. 
5.5.3 Review of literature 
Aburahma et al (2011) report that elevated CSF/plasma glycine level is encountered in a 
variety of clinical conditions and hence cannot be considered to be pathognomonic of 
nonketotic hyperglycinemia (NKH). This report is significant because NKH is a disease with 
very bad prognosis. Lang et al (2008) discusses the difficulties of diagnosing transient NKH.  
 
Fig. 3. Chromatogram of patient 5 showing elevated glycine levels (Glycine 1311 mol/L, 
Normal Glycine < 275 mol/L) 
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Leipnitz et al (2009) report lipid peroxidation and reduced antioxidant levels in NKH. 
Kanno et al (2007) reviews the genetic causes of NKH. NKH can be caused by genes in the 
glycine cleavage system, including GLDC, AMT and GCSH. They report significant number 
of GLDC mutations by MLPA (multiple ligation-dependent probe amplification) analysis. 
Conter et al (2006) and Kure et al (2006) also report significant number of mutations in these 
genes. 
Tan et al (2007) report that currently tandem mass spectrometry employed for newborn 
screening does not identify NKH without significant error rate. Raghavendra et al (2007) 
and others report significant neurological abnormalities in patients with NKH. Generally 
NKH is a disease refractory to treatment. A number of authors report the use of sodium 
benzoate and dextromethrophan in the treatment of NKH, some of them with and others 
without any beneficial effect. 
6. Section 2: Hyperhomocysteinemia  
6.1 Materials and methods 
Homocysteine estimation was done by ELISA method (BioRad Laboratories Inc.). 5 ml 
blood was drawn from the patients. 953 patients were analyzed during this 5 year period, 
110 patients were from the Department of Cardiology, 656 from the Department of 
Neurology and the remaining from other departments. 
6.2 Results 
285 patients had elevated homocysteine levels. 226 cases had hyperhomocysteinemia from 
the Department of Neurology (226/656, 34.5%), 31 had hyperhomocysteinemia from the 
Department of Cardiology (31/110, 28.2%), and the remaining were other cases like 
peripheral artery disease, deep vein thrombosis etc. Neurological disorders included 
different types of stroke including medullary stroke, ischemic stroke, young stroke, transient 
ischemic attack, sagittal sinus thrombosis, lacunar thalamic stroke and recurrent stroke. All 
patients with hyperhomocysteinemia from the Department of Cardiology were suffering 
from Coronary artery disease (CAD). 
6.3 Biochemical abnormalities 
Normal homocysteine level in blood is 5-15 mol/L. In diseases, it may be increased to 50 to 
100 times. Moderate increase is seen in aged persons, vitamin B12 or B6 deficiency, tobacco 
smokers, alcoholics and in hypothyroidism. Substantial increase is noticed in congenital 
enzyme deficiencies. Large amounts of homocysteine are excreted in urine. In plasma, 
homocysteine (with -SH group) and homocysteine (disulfide, -S-S- group) exist. Both of 
them are absent in normal urine; but if present, it will be the homocysteine (disulfide) form. 
If homocysteine level in blood is increased, there is increased risk for coronary artery 
diseases. Homocystinuria/ hyperhomocysteinemia may be due to many causes. These 
include impaired activity of CBS (genetic CBS deficiency, INH therapy), methionine 
synthase defect, MTHFR defect, impaired metabolism of vitamin B12, renal insufficiency, 
pyridoxine and folate deficiency etc. 
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6.4 Review of literature 
Hyperhomocysteinemia is associated with a number of diseases including coronary artery 
diseases, stroke, retinal vein thrombosis, diabetic peripheral neuropathy, schizophrenia, 
preeclampsia, chronic pancreatitis etc. Herrmann and Obeid (2011) have reviewed the role 
of hyperhomocysteinemia in neurodegenerative diseases like Alzheimer’s disease, vascular 
dementia, cognitive impairment and stroke. Damelan et al (2010) report 
hyperhomocysteinemia is ischemic stroke patients from France. Valentino et al ((2010) 
report elevated blood and CSF levels of homocysteine in amyotropic lateral sclerosis (ALS).  
Sniezawska et al (2011) report that antiepileptic drug (AED) treatment in epileptics leads to 
increase in homocysteine and asymmetric dimethyl arginine (ADMA) levels. Greater 
increase in homocysteine is observed in patients with MTHFR CT (C677T) and MTHFD1 GG 
(G1958A) polymorphisms. Linnebank et al (2011) report reduced serum Vitamin B12 and 
folate levels on treatment with AED. Zhuo et al (2010) report that normalization of 
homocysteine values in rat models with hyperhomocysteinemia resulted in improvement of 
cognitive defects and brain amyloidosis. 
Paoli et al (2010) report that protein N homocysteinylation induces the formation of toxic 
amyloid like amyloid protofibrils. The authors hypothesize that this could be responsible for 
pathophysiology of hyperhomocysteinemia. da Cunha et al (2010) report increase in 
inflammatory markers in brain and blood of mice after acute homocysteine administration. 
This study suggests that inflammation may be at least partially responsible for neurological 
and cardiovascular response of homocysteine. Green et al (2010) report that homocysteine 
lowering vitamins do not lower S adenosyl homocysteine levels in older people. They 
suggest that S adenosyl homocysteine might be a better indicator for vascular events. They 
hypothesize that this might explain the lack of clinical benefit of B vitamins in some patients 
with hyperhomocysteinemia. Almawi et al (2009) and others have investigated the role of 
MTHFR C677T polymorphism and high homocysteine levels in patients with stroke. Dutta 
et al (2009) report mild increase in serum homocysteine levels in Indian patients with 
idiopathic mental retardation.  
7. Section 3: Pheochromocytoma, neuroblastoma 
7.1 Materials and methods 
VMA estimation was done using column method (BioRad VMA by column test). 24 hr urine 
samples were collected following dietary restrictions for 3 days. Samples were collected in 
6N HCl and stored in the refrigerator during collection time. If the pH was more than 3.5, 
the samples were rejected. The analysis was done following manufacturer’s guidelines. 582 
samples were collected during this time period.  
7.2 Results 
44 patients had elevated VMA levels. This included 24 cases of pheochromocytoma, 15 cases 
of neuroblastoma and 5 cases of paraganglioma. The analysis correlated positively with 
histopathology studies. All patients with pheochromocytoma and paraganglioma were 
above 10 years of age; whereas 60% cases of neuroblastoma cases were below 10 years of 
age. The sensitivity and specificity of our results were 88% and 86% respectively. All 
neuroblastoma cases showed elevated VMA level. 
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7.3 Biochemical abnormalities 
Catecholamines are important biological compounds, essential to maintain the proper 
functioning of the body. Secretion of excessive catecholamines can produce stress, 
palpitation, paroxysmal hypertension, congestive heart failure, thyroid hormone deficiency 
and arrhythmias. Measurement of catecholamines and its metabolites is primarily used in 
the diagnosis of Neuroendocrine tumors; Neuroblastomas, Pheochromocytomas and 
paragangliomas. Most common metabolites of catecholamines are Vanillylmandelic acid 
(VMA), urinary free catecholamines, metanephrine, normetanephrine, homovanillic acid 
(HVA), plasma catecholamines, plasma metanephrines and chromogranin A. Most of the 
metabolites are measured by spectrophotometric assays, nowadays replaced by HPLC and 
mass spectrometry. Vanillylmandelic acid (VMA) is a major catecholamine metabolite 
formed by the actions of catechol-O-methyl transferase and MAO. VMA is excreted by 
kidney and represents 40%-50% urinary excretory product of norepinephrine and 
epinephrine. Norepinephrine is the major source of VMA.  
Neuroblastomas are the most common solid extra-cranial tumors in children, and account 
for 7-10 % of all tumors. In about 90% of cases of neuroblastoma, elevated levels of 
catecholamines or its metabolites are found in the urine or blood. Pheochromocytomas are 
chromaffin-cell tumors; 80-85 % arises from the adrenal medulla and 15-20 % arises from 
extra-adrenal chromaffin tissues (paragangliomas). They are characterized by excessive 
production of catecholamines. If not diagnosed or if left untreated, the excessive secretion of 
catecholamines by these tumors can have devastating consequences. Paraganglioma is a rare 
neuroendocrine tumor that arises from extraadrenal sympathochromaffin tissue, usually in 
the abdomen. 10% of the catecholamine producing tumors are paragangliomas that develop 
in head, neck, thorax and abdomen. About 97% are benign and 3% metastatic.  
7.4 Review of literature 
Elevated urinary catecholamines have been described in 90 – 95 % of patients with 
neuroblastomas [Smith et al (2010)]. Studies suggest that dopamine nervous systems are 
involved in the pathogenesis of autistic disorder. Quantification of urine homovanillic acid 
(HVA) and vanillylmandelic acid (VMA) by GC/MS are very important in the study of 
dopamine metabolism in autistic children [Kaluzna-Czaplinska et al (2010)]. Allenbrand and 
Garg (2010) also report quantification of urine HVA and VMA by GC/MS. Li et al (2010) 
describe that the ratio of HVA/VMA ratio is useful as a disease marker in neuroblastomas 
and pheochromocytomas. Aydin et al (2010) report that VMA is a poor prognostic factor in 
patients with neuroblastoma.  
Hickman et al (2009) report that in patients with pheochromocytoma, plasma free 
metanephrines displayed superior diagnostic sensitivity and specificity compared with 
other biochemical markers of catecholamine output and metabolism. Boyle et al (2007) came 
to a similar conclusion. Lionetto et al (2008) describe an HPLC-tandem mass spectrometric 
method for the simultaneous quantification of VMA, HVA and 5-HIAA in human urine. 
8. Conclusions 
We have detected a high incidence of metabolic disorders in our population. The 
commonest disorders detected were organic acidurias, congenital adrenal hyperplasia and 
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hyperhomocysteinemia. Aminoacidurias like PKU are rare; whereas organic acidurias 
(PAA, MMA and MSUD) are more common. Prompt identification and treatment is 
important and early diagnosis helps to institute treatment measures which prevents further 
morbidity and reduces mortality rates.  
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